Amit Etkin, MD, PhD

Phase 2 depression trial shows ALTO-203 boosts attention, EEG theta-beta ratio and alertness, pointing to biomarker-guided dosing and precision psychiatry.

Alto Neuroscience pioneers drug development for cognitive impairment in schizophrenia, targeting biomarkers to enhance treatment precision and patient outcomes.

Etkin describes precision psychiatry data for MDD presented at the Society for Biological Psychiatry Annual Meeting.

Learn more about Alto Neuroscience's ALTO-300, in ongoing phase 2b trials as an adjunct treatment for major depressive disorder.

How can we enhance our understanding of the human brain?